Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CASI PharmaceuticalsCASIF +1.40%29 Cash-to-Debt is 0.21 as of Dec. 2025, which is 99% below its 10-year median of 21.60. GuruFocus rates CASIF with a GF Score™ of 29/100 and a GF Value™ of $1.09 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,399 Biotechnology companies, CASI Pharmaceuticals ranks worse than 91.78% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CASI Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.21.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, CASI Pharmaceuticalscouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for CASI Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
CASIF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21 Med: 21.6 Max: No Debt
Current: 0.21
During the past 13 years, CASI Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.21. And the median was 21.60.
CASIF's Cash-to-Debt is ranked worse than 91.78% of 1399
companies
in the Biotechnology industry
Industry Median: 6.51
vs CASIF: 0.21
CASI Pharmaceuticals (OTCPK:CASIF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
CASI Pharmaceuticals Cash-to-Debt Related Terms
CASI Pharmaceuticals Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for CASI Pharmaceuticals's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CASIF vs DCOY, PKTX, BIXT: Cash-to-Debt Comparison
For the Biotechnology subindustry, CASI Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals (CASIF) has a Cash-to-Debt of 0.21 as of Dec. 2025. This is 99% below median its historical median of 21.60. Over the past decade, CASI Pharmaceuticals' Cash-to-Debt has ranged from 0.21 to 10,000.00. According to the industry distribution chart, CASI Pharmaceuticals ranks #1284 out of 1399 companies in the Biotechnology industry, placing it in the top 91.8%.
Is CASI Pharmaceuticals' Cash-to-Debt too high?
CASI Pharmaceuticals' current Cash-to-Debt of 0.21 is 99% below median its 10-year median of 21.60. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.51. CASI Pharmaceuticals' value of 0.21 is 96.8% below this industry median. Based on the distribution chart, CASI Pharmaceuticals ranks #1284 out of 1399 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Cash-to-Debt compare to DCOY and PKTX?
According to the Biotechnology industry distribution chart, CASI Pharmaceuticals ranks #1284 out of 1399 companies for Cash-to-Debt. This places CASI Pharmaceuticals in the lower half of its industry. The industry median Cash-to-Debt is 6.51. CASI Pharmaceuticals' value of 0.21 is 96.8% below this benchmark. Historically, CASI Pharmaceuticals' own Cash-to-Debt has ranged from 0.21 to 10,000.00 over the past decade. While the company's 10-year median is 21.60 vs. the industry median of 6.51, CASI Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.51, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CASI Pharmaceuticals's current Cash-to-Debt of 0.21 is 96.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CASI Pharmaceuticals's current Cash-to-Debt is 0.21, which is 99% below median its own 10-year median of 21.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CASI Pharmaceuticals (CASIF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.09, compared to a current price of $0.15 — trading 86.4% below its estimated fair value. The current Cash-to-Debt is 0.21, which is 99% below median its 10-year median of 21.60 and 96.8% below the Biotechnology industry median of 6.51. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For CASI Pharmaceuticals (CASIF), the current Cash-to-Debt is 0.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.15 is trading 86.4% below its estimated GF Value™ of $1.09.
GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.
Key valuation signals for CASIF:
Cash-to-Debt: 0.21 (99% below median its 10-year median of 21.60)
GF Value™: $1.09 vs. price of $0.15 (86.4% below fair value)
Industry Position: 96.8% below the Biotechnology median (#1284 of 1399)
No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score
Get the complete analysis for CASIF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASIF has been successfully added to your 
